Ocular Therapeutix Inc
NASDAQ:OCUL
Ocular Therapeutix Inc
NASDAQ:OCUL
Price:
8.07
USD
-3.12%
Market Closed
Market Cap:
$1.8B
Add Note
Add Target
Capture your thoughts and set a target
Decide at what price you'd be comfortable buying and we'll help you stay ready.
Based on
Margin of Safety
0%
10%
20%
30%
40%
50%
Your Price Target
Linked to
current price
· In Buy Zone
Loading
Note attached
Choose the stock you wish to monitor with a price target
Recently Viewed
|
Ocular Therapeutix Inc
NASDAQ:OCUL
|
US |
|
Celldex Therapeutics Inc
NASDAQ:CLDX
|
US |
Multiples-Based Value
The Multiples-Based Value of one
OCUL
stock under the Base Case scenario is
2.48
USD.
Compared to the current market price of 8.07 USD,
Ocular Therapeutix Inc
is
Overvalued by 69%.
Multiples-Based Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Relative Valuation FAQ:
OCUL
Multiples-Based Value
Base Case
2.48
USD
Overvaluation 69%
Multiples Across Competitors
OCUL Competitors Multiples
Ocular Therapeutix Inc Competitors
Ocular Therapeutix Inc Competitors
All Countries
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| US |
|
Ocular Therapeutix Inc
NASDAQ:OCUL
|
1.7B USD | 31.9 | -6.2 | -3.9 | -3.8 | |
| US |
|
Eli Lilly and Co
NYSE:LLY
|
847.5B USD | 13 | 41.1 | 27.7 | 29.6 | |
| US |
|
Johnson & Johnson
NYSE:JNJ
|
576.1B USD | 6.1 | 21.5 | 14.9 | 18.4 | |
| CH |
|
Roche Holding AG
SIX:ROG
|
248.4B CHF | 4 | 19.3 | 11.4 | 12.9 | |
| US |
|
Merck & Co Inc
NYSE:MRK
|
294.3B USD | 4.5 | 16.1 | 10 | 12.1 | |
| UK |
|
AstraZeneca PLC
LSE:AZN
|
218.1B GBP | 4.9 | 28.1 | 15.6 | 22 | |
| CH |
|
Novartis AG
SIX:NOVN
|
229.5B CHF | 5.2 | 21.1 | 13.1 | 16.8 | |
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
237.1B USD | 102.3 | -81.1 | 375.3 | 941.3 | |
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1T DKK | 3.5 | 10.5 | 7.8 | 9.1 | |
| US |
|
Pfizer Inc
NYSE:PFE
|
156.8B USD | 2.5 | 20.2 | 7.7 | 10.3 | |
| US |
|
Bristol-Myers Squibb Co
NYSE:BMY
|
119.6B USD | 2.5 | 17 | 7.2 | 8.8 |
P/S Multiple
P/E Multiple
EV/EBITDA Multiple
EV/EBIT Multiple
